PIK3CA-Related Overgrowth Spectrum clinical trials at UCSF
1 research study open to eligible people
PIK3CA-related overgrowth spectrum leads to abnormal body growth. UCSF is evaluating the safety and effectiveness of Alpelisib for people with this condition. The trial involves multiple centers and runs for 16 weeks.
PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
open to all eligible people
This is a prospective Phase II multi-center study with an upfront 16-week, randomized, double-blind, placebo-controlled period, and extension periods, to assess the efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult participants with PIK3CA-related overgrowth spectrum (PROS).
San Francisco, California and other locations
Our lead scientists for PIK3CA-Related Overgrowth Spectrum research studies include Beth Apsel Winger.
Last updated: